Charley Grant, Wall Street Journal

Charley Grant

Wall Street Journal

New York, NY, United States

Contact Charley

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Wall Street Journal

Recent articles by Charley:

Goldman Sachs Rolls Out New Worker Benefits to Combat Employee Burnout

The Wall Street firm is offering paid leave for pregnancy loss and expanding the amount of time employees can take for bereavement leave among other new benefits in a bid to attract and keep employees. → Read More

Drug Industry Gets Mild Treatment From Congress

Measures agreed to among congressional Democrats this week to lower prescription-drug costs for seniors could have been far more draconian. → Read More

McDonald’s, Coca-Cola Power Through Despite Inflation

Strong earnings from McDonald’s, Kraft Heinz and Coca-Cola show America’s food and beverage giants have what it takes to overcome inflationary pressures. → Read More

Inflation Pinches Restaurants, but Customers Seem Willing to Split the Check

Casual-dining stocks such as Chili’s owner Brinker International are logging a major hit to profits from food and labor costs even with a rebound in dining but should be able to pass more of it through in the future. → Read More

Biogen Shareholders Face the Waiting Game

Investor enthusiasm for Biogen won’t come back until key questions about its new Alzheimer’s disease drug are resolved. → Read More

Johnson & Johnson’s Stock Deserves a Booster

Wall Street’s excessive focus on vaccine sales has created an opportunity for investors to buy J&J shares at a discount. → Read More

Domino’s Pizza Shares Can Stay Hot

Higher labor and fuel costs will be a focus for the pizza chain’s quarterly result, but the long-term growth opportunity should trump short-term concerns. → Read More

Merck’s Covid-19 Drug Is a Boon for Wall Street and Main Street

The strong data for Merck’s experimental Covid-19 antiviral treatment has rejuvenated the company’s stock price and could jump-start the moribund biotech sector. → Read More

Catch the Early Bird Special on Restaurant Stocks

Higher labor and food costs, coupled with rising cases of the Delta variant, have created an attractive backdrop for restaurant stock prices. → Read More

Big Pharma Isn’t Done Rolling Out Covid Treatments

Oral antiviral treatments for Covid-19 could give a public health boost and generate blockbuster sales for the drug industry. → Read More

Sick Day for Biotech Stocks Won’t Last

Tough talk from the Biden Administration on drug prices and weak sales have harmed biotech stocks, but these symptoms likely won’t last. → Read More

Keep an Eye on Wall Street’s Clean Medicine Experiment

Gwyneth Paltrow, Don Cheadle and others are betting that clean-living principles are headed to your medicine cabinet. Investors should be paying close attention. → Read More

Medical-Device Stocks Seem Immune to Delta Surge

Higher Covid-19 case counts mean that more disruption at hospitals is likely. This time, Wall Street is ready. → Read More

Investors Can Clean Up With Steris

Steris looks like a bargain compared with some of the highflying stocks that characterize today’s market. The strong cash flow generation and predictable sales growth at Steris resemble a high-quality subscription business. → Read More

Pharma’s Appetite for Biotech Deals Bodes Well

This year has been disappointing for biotech investors, but Pfizer’s planned acquisition of Trillium Therapeutics shows things aren’t as bleak as they seem. → Read More

Tesla’s Ascent Can’t Remain on Autopilot

Investors betting on regulatory crackdowns at the electric-vehicle maker led by Elon Musk have historically lost that wager. But that doesn’t mean Tesla stock is in the clear. → Read More

CVS Stock Will Be Fine Once Covid-19 Vaccines Wear Off

Covid-19 vaccines boosted the chain’s second-quarter performance, but strong results from its Aetna unit suggest an extended run of good health is in store. → Read More

Biogen’s Alzheimer’s Drug Is a Wall Street Winner, Controversy or Not

U.S. health regulators approved the biotech company’s drug. And all of a sudden, a plodding value stock has a compelling growth story. → Read More

Why Doing Good Is No Longer Bad Business

The focus on environmental, social and governance changes at America’s biggest companies is a response to demand from consumers and investors. → Read More

Amazon and Walmart Have an Rx for Healthcare. The Cure Won’t Be Easy.

Tech, banking and retail giants face numerous obstacles in their efforts to fix—and profit from—an industry that attracts $4 trillion annually → Read More